August 20, 2018Indian Heart JournalOpen Access

Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications

View Full Paper

Ask AI

Bookmark

Structured PICO

Population

Patients with chronic heart failure, ischemic heart disease, sepsis, and multiple organ dysfunction syndrome, including those with contraindications to beta-blockers or who cannot tolerate them.

Intervention

Ivabradine (alone or in combination with currently recommended pharmacological therapy)

This review summarizes the evidence supporting ivabradine's efficacy and safety in reducing heart rate and improving clinical outcomes in chronic heart failure and other emerging indications.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May support ivabradine for HR reduction in CHF; leaves open effects on hospitalizations.

Cite This Study

Sathyamurthy et al. (2018) studied this question.

synapsesocial.com/papers/6a711c8ae36a167817e2f061 https://doi.org/10.1016/j.ihj.2018.08.008

View Full Paper

Ask AI

Bookmark

Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications

Structured PICO

Discussion

Implication

Cite This Study

Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider